Dexcom Reports Fourth-Quarter Sales Growth in Diabetes Care and Insulin-Free CGM Devices
Fourth-Quarter Sales Performance
Bengaluru: Medical device maker Dexcom exceeded fourth-quarter sales estimates with a strong demand for its continuous glucose monitors (CGMs) used by diabetes patients. The company reported a revenue of $1.11 billion, slightly above the analysts' consensus estimate of $1.10 billion.
Revenue Forecast and Market Strategy
The California-based device maker has reiterated its previous revenue estimate of $4.60 billion for 2025, despite a forecast of $4.61 billion from analysts. Dexcom's revenue has faced challenges due to restructuring efforts and lower customer numbers; however, it expects the launch of the Stelo device to regain momentum.
Introducing Stelo and International Expansion
- The Stelo is a groundbreaking insulin-free CGM, marking its place as the first available for over-the-counter sales.
- Increased diabetes care awareness and wider insurance coverage have fueled demand for CGMs.
- Dexcom's international expansion efforts have improved access in markets like Japan and France.
Market Competition
Rival Abbott has also launched its OTC CGM, Lingo, within weeks of Stelo's release, highlighting the competitive landscape in diabetes care technology.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.